AI Terminal
Dr. Martens PLC
Board/Management Information • Apr 14, 2023
5055_rns_2023-04-14_1cbc2fb6-233b-455a-9c20-3bf25e599699.html
Board/Management Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1908W
Dr. Martens PLC
14 April 2023
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
14 April 2023
Dr. Martens plc
("the Company")
CFO retirement
Dr. Martens Plc today announces that, with agreement of the Board, Jon Mortimore has decided to retire from his role as Chief Financial Officer (CFO) of the Company. Jon will continue in his role until a successor is in place to ensure a smooth transfer of responsibilities.
The Company is commencing an external search for Jon's successor.
Jon joined the company in April 2016. During his seven years at Dr. Martens, Jon has been instrumental in delivering the Company's transition from a family-run company to a listed PLC, overseeing revenue growth from £230m to £1bn, as well as playing an integral role in the Company's initial public offering (IPO) in January 2021.
Paul Mason, Dr. Martens Chair said "On behalf of the Board, I would like to thank Jon for his central role in driving the strong growth and strategic development of Dr. Martens over the last seven years. His knowledge of the business and understanding of the Company's value drivers have played a key part in helping develop the business during this period. We also want to thank him for his careful stewardship of the finance function, in particular during the pandemic period, which is testament to his dedication and exceptional hard work. We wish him well in his retirement."
Jon Mortimore, CFO added "I am proud of the progress that Dr. Martens has achieved during my time as CFO since 2016 and I look forward to seeing further growth and success in the years to come. This is a great company with an incredible brand and passionate people, and I believe it has a very exciting long-term future ahead of it. I will be retiring once my successor is in place but until then, I will continue to support Dr. Martens in my role as CFO."
Enquiries
Investors and analysts
Mark Blythman, Interim Director of Investor Relations [email protected] +44 7570 871207
Beth Callum, Senior Investor Relations Analyst [email protected] +44 203 995 2644
Press
Maitland +44 207 379 5151
Clinton Manning +44 7711 972662
Gill Hammond, Director of Communications +44 7384 214248
This announcement contains inside information. The person responsible for arranging the release of this announcement on behalf of the Company is Emily Reichwald, Chief People and Sustainability Officer and Company Secretary.
About Dr. Martens
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAIJMLTMTABBPJ